epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove bupivacaine/ epinephrine
    generic
  • remove Erzofri
    paliperidone palmitate
  • remove methyldopa
    generic

multicheck MultiCheck Results - 4 Interactions

Smiley face Smiley face

Monitor/Modify Tx

Smiley face Smiley face bupivacaine/epinephrine (generic) + Erzofri (paliperidone palmitate)

Monitor/Modify Tx


bupivacaine + paliperidone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

Smiley face Smiley face bupivacaine/epinephrine (generic) + methyldopa (generic)

Monitor/Modify Tx


bupivacaine + methyldopa

monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)

epinephrine + methyldopa

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

Smiley face Smiley face Erzofri (paliperidone palmitate) + methyldopa (generic)

Monitor/Modify Tx


paliperidone + methyldopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

Additional Considerations

Smiley face Smiley face epinephrine in bupivacaine/epinephrine

nasal epinephrine use: caution advised with nasal drugs, including subsequent nasal epinephrine doses, up to 2 wk after initial administration; nasal epinephrine may incr. systemic absorption of nasal drugs, risk of adverse effects

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information